Abstract
Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Current Pharmaceutical Design
Title:Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer
Volume: 24 Issue: 11
Author(s): Atefeh Arab, Rezvan Yazdian Robati, Jessica Nicastro, Roderick Slavcev and Javad Behravan*
Affiliation:
- School of Pharmacy, University of Waterloo, 200 University Ave, Waterloo,Canada
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Abstract: Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Export Options
About this article
Cite this article as:
Arab Atefeh , Robati Yazdian Rezvan, Nicastro Jessica, Slavcev Roderick and Behravan Javad *, Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer, Current Pharmaceutical Design 2018; 24 (11) . https://dx.doi.org/10.2174/1381612824666180327152117
DOI https://dx.doi.org/10.2174/1381612824666180327152117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Synthesis, Molecular Docking Study, and Cytotoxic Activity of 3,4-diaryl-5-(4-pyridinyl)-1,2,4-oxadiazole
Medicinal Chemistry Efficacy of Yun Zhi (Coriolus versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Current Bioactive Compounds Polycation-Based Gene Therapy: Current Knowledge and New Perspectives
Current Gene Therapy Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets COX-2 and Colorectal Cancer
Current Pharmaceutical Design Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Up-Regulation of MBD1 Promotes Pancreatic Cancer Cell Epithelial-Mesenchymal Transition and Invasion by Epigenetic Down-Regulation of E-Cadherin
Current Molecular Medicine Screening of Drug Efficacy of Rosmarinic Acid Derivatives as Aurora Kinase Inhibitors by Computer-Aided Drug Design Method
Current Computer-Aided Drug Design Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Human Aurora / Ipl1p Related Kinases
Current Genomics Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry